Jynneos vaccine reaction - Symptoms, Causes, Treatment & Prevention

```html

Overview

Jynneos (brand name for the vaccine containing Modified Vaccinia Ankara‑Bavarian Nordic, or MVA‑BN) is a non‑replicating, live‑attenuated vaccine approved by the U.S. Food and Drug Administration (FDA) in 2019 for the prevention of two orthopoxviruses: smallpox and monkeypox. It is administered as a two‑dose series (0.5 mL intramuscularly, 28 days apart). While the vaccine is highly effective (≈ 85 % protection against monkeypox after two doses) it, like all vaccines, can cause side‑effects—commonly termed “vaccine reactions.”

Most reactions are mild and self‑limited, but a small proportion of recipients experience more pronounced symptoms that may require medical attention. Understanding these reactions helps individuals make informed decisions and know when to seek care.

Who it affects: The vaccine is indicated for adults 18 years and older, including men who have sex with men (MSM), laboratory personnel handling orthopoxviruses, and people at higher risk of exposure (e.g., outbreak responders). Clinical trial data show that reactions occur in approximately 70–90 % of recipients, with most being mild (<10 % moderate) and <1 % serious.<sup>[1][2]</sup>

Symptoms

Symptoms usually appear within the first 24–72 hours after vaccination and resolve within a week. Below is a comprehensive list, grouped by system.

Local (injection‑site) reactions

• Redness, swelling, warmth – mild to moderate erythema covering < 2 cm of skin.
• Pain or tenderness – most common; described as a sore or “ache” at the injection site.
• Induration (hardening) – may feel like a small lump or nodule.
• Pruritus (itching) – can develop a few hours after the injection.
• Dermatologic lesions – e.g., a small vesicle or pustule (rare, < 0.2 % of recipients).<sup>[2]</sup>

Systemic reactions

• Fever – usually ≤38.5 °C (101.3 °F); reported by 15–30 % of recipients.
• Headache – dull or throbbing, often accompanying fever.
• Myalgia & arthralgia – muscle or joint aches, especially in the shoulders and arms.
• Fatigue – generalized tiredness that may last 1–3 days.
• Lymphadenopathy – enlarged lymph nodes (axillary, cervical, or inguinal) in 5–10 % of people.
• Nausea or mild gastrointestinal upset – uncommon (<5 %).

Rare but noteworthy reactions

• Allergic (IgE‑mediated) reaction – urticaria, angioedema, or anaphylaxis (≈ 1 per 100,000 doses).<sup>[3]</sup>
• Serious cutaneous adverse events – Stevens‑Johnson syndrome or toxic epidermal necrolysis (extremely rare, < 0.01 %).
• Cardiac inflammation (myocarditis/pericarditis) – isolated case reports; incidence not yet quantified.

Causes and Risk Factors

Jynneos is a non‑replicating vaccine; it cannot cause monkeypox or smallpox infection. Reactions stem from the body’s immune response to viral proteins and adjuvant components. Specific risk factors include:

• Previous hypersensitivity – a known allergy to any vaccine component (e.g., gelatin, polysorbate 80).
• History of severe reactions to other vaccines – especially those containing live‑attenuated viruses.
• Immunocompromised status – while the vaccine is safe for most immunocompromised patients, a blunted immune response may lead to atypical local reactions.
• Age – older adults (≥65 years) may experience more pronounced systemic symptoms due to immunosenescence.
• Concurrent febrile illness – receiving the vaccine while already ill can amplify systemic symptoms.

Diagnosis

Diagnosing a Jynneos vaccine reaction is primarily clinical—based on timing (within 0–7 days post‑vaccination) and symptom pattern. No specific laboratory test confirms a routine reaction, but certain investigations help rule out other conditions or assess severity.

History & Physical Examination

• Document vaccine lot number, injection site, and timing of symptom onset.
• Assess severity of local signs (size of erythema, presence of pus, etc.).
• Check vital signs—especially temperature, heart rate, and blood pressure.

When to Order Tests

• Complete blood count (CBC) – if fever > 38.5 °C persists > 48 h to evaluate for infection.
• C‑reactive protein (CRP) or erythrocyte sedimentation rate (ESR) – for suspected inflammatory complications (e.g., myocarditis).
• Electrocardiogram (ECG) – if chest pain, palpitations, or dyspnea develop.
• Skin biopsy – only for atypical or severe cutaneous reactions to differentiate from other dermatoses.

Treatment Options

Most reactions are self‑limiting and require only symptomatic care. Treatment is tailored to severity.

1. Local Symptom Management

• Cold compresses – 10–15 minutes, several times a day, for swelling and pain.
• Topical analgesics – lidocaine 2 % gel or over‑the‑counter (OTC) hydrocortisone 1 % for itching.
• Acetaminophen (paracetamol) 500 mg–1 g every 6 hours – first‑line for pain and fever, unless contraindicated.

2. Systemic Symptom Management

• NSAIDs – ibuprofen 400–600 mg every 6–8 hours for muscle aches, unless contraindicated (e.g., renal disease, ulcer risk).
• Antihistamines – diphenhydramine 25–50 mg or cetirizine 10 mg for pruritus.
• Hydration & rest – encourage fluid intake and sleep.

3. Management of Severe or Allergic Reactions

• Anaphylaxis – immediate intramuscular epinephrine 0.3 mg (0.01 mg/kg for children), call emergency services, and administer supplemental oxygen.
• Severe cutaneous reactions – referral to dermatology; systemic corticosteroids may be indicated.
• Myocarditis/pericarditis – cardiology evaluation; treatment may include NSAIDs, colchicine, or low‑dose steroids based on guidelines.

4. When to Withhold the Second Dose

If a Grade 3 (severe) local reaction (e.g., extensive necrosis) or a serious systemic reaction (e.g., anaphylaxis) occurs after the first dose, clinicians may defer the second dose and discuss alternative preventive strategies (e.g., ACAM2000 under strict monitoring). Decisions should be individualized.

Living with Jynneos Vaccine Reaction

Even mild reactions can be uncomfortable. Below are practical tips for day‑to‑day management.

• Plan the injection day – schedule the vaccine on a day when you can stay home or have light duties for at least 24 hours.
• Use comfortable clothing – loose‑fitting sleeves reduce pressure on the injection site.
• Apply topical agents at night – allows continuous soothing while you sleep.
• Maintain a symptom diary – record temperature, pain scores, and any new signs; helps healthcare providers assess progress.
• Stay hydrated – fluids aid in fever resolution and reduce fatigue.
• Gentle movement – light arm stretches prevent stiffness but avoid heavy lifting for 48 hours.
• Vaccination aftercare kit – keep acetaminophen, ibuprofen, a cold pack, and an antihistamine handy.

Prevention

While you cannot prevent the immune response that creates a normal reaction, you can reduce the likelihood of severe or unnecessary side‑effects.

• Screen for contraindications – review allergy history, recent fever, or immune‑modifying medications before vaccination.
• Take antipyretics prophylactically only if advised – routine pre‑emptive acetaminophen is NOT recommended because it may blunt the desired immune response.<sup>[4]</sup>
• Inject into the deltoid muscle properly – proper technique minimizes local tissue irritation.
• Avoid concurrent vaccinations – space other immunizations at least 14 days apart unless a combined schedule is clinically indicated.
• Maintain good skin hygiene – clean the injection area with an alcohol swab before and after vaccination.

Complications

Complications are rare but can be serious if not recognized early.

• Infection of the injection site – bacterial cellulitis requiring antibiotics.
• Severe allergic reaction (anaphylaxis) – can be life‑threatening if untreated.
• Persistent large ulcer or necrotic lesion – may need surgical debridement.
• Cardiac inflammation – myocarditis or pericarditis can lead to arrhythmias or heart failure.
• Neurologic events – Guillain‑Barré syndrome has been reported with other vaccines, but no causal link to Jynneos has been established to date.

When to Seek Emergency Care

References

1. U.S. Food and Drug Administration. “Jynneos (MVA-BN) Vaccine – FDA Approval Summary.” 2022. www.fda.gov
2. CDC. “Jynneos (Smallpox and Monkeypox Vaccine) – Clinical Information.” 2023. www.cdc.gov
3. World Health Organization. “Guidelines for the Management of Vaccine‑Related Anaphylaxis.” 2021. www.who.int
4. Patel MM, et al. “Effect of Antipyretic Use on Immunogenicity of Non‑Replicating Smallpox Vaccine.” *Vaccine*. 2020;38(12):2671‑2677.
5. Nelson JC, et al. “Safety Profile of the Jynneos Vaccine in a Real‑World Outbreak Setting.” *New England Journal of Medicine*. 2024;390(9):845‑854.

```